Top Tweets for #KuASHreview
That’s a wrap on #kuASHreview! Thanks for joining us and thank you to our sponsors! Course materials are available here ➔ https://t.co/OSoxplq5u6. #KUBloodCancer
.@KUcancercenter’s Dr. Anurag Singh (@aksinghmd) and Dr. Zaid Abdel Rahman (@ZaidAR_MD) from @KHCFKHCC are co-presenting “Approach to Hereditary Hematologic Malignancies and Inherited Bone Marrow Failure Syndromes” at #kuASHreview. #KUBloodCancer
Register today for the 2025 KU ASH Review: Current Updates in Hematologic Diseases, which will be held on Saturday, January 18th at the Sheraton Overland Park Hotel in Overland Park, Kansas. Learn more and register at https://t.co/EySzkWKeE7.
#ASH24 #KUBloodCancer #kuASHreview @KUMedCenter
Thank you to everyone who attended the #kuASHreview this past weekend! As our region’s only @theNCI designated comprehensive cancer center, we are proud to provide access to the latest clinical trials. Connect with our clinical trials finder app ➔ https://t.co/RERYsT3tWd.
Happening right now… Dr. Alma Habib, @OSUCCC_James, is covering Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with #AML. #kuASHreview
This past weekend, @KUCancerCenter hosted the 2023 ASH Review: Current Updates in Hematologic Diseases. Many thanks to our excellent speakers and guests for a successful conference!
#KUBloodCancer #kuASHreview #ASH22 #WeAreNCIComprehensive
OS in Penta RRMM is dismal! And obtaining a BCMA-directed therapy is critical! Though the waiting list for CAR-T is still a concern as 1 out of 4 pts died while on the waiting list! #KuASHreview #mmsm #myeloma #USMIRC #medtwitter #MedEd @KUcancercenter
Bispecific Abs targeting (BCMA, GPRC5D, FcRH5) [efficacy and side effects] in myeloma future of treatment of post-BCMA CAR-T and Penta RRMM is within this group #KuASHreview #mmsm #myeloma #USMIRC #medtwitter #MedEd @KUcancercenter
![Abdallah81MD's tweet photo. Bispecific Abs targeting (BCMA, GPRC5D, FcRH5) [efficacy and side effects] in myeloma future of treatment of post-BCMA CAR-T and Penta RRMM is within this group #KuASHreview #mmsm #myeloma #USMIRC #medtwitter #MedEd @KUcancercenter https://t.co/5VifmeiFGB](https://pbs.twimg.com/media/FnFo3ZCXkAE2VzF.jpg)
![Abdallah81MD's tweet photo. Bispecific Abs targeting (BCMA, GPRC5D, FcRH5) [efficacy and side effects] in myeloma future of treatment of post-BCMA CAR-T and Penta RRMM is within this group #KuASHreview #mmsm #myeloma #USMIRC #medtwitter #MedEd @KUcancercenter https://t.co/5VifmeiFGB](https://pbs.twimg.com/media/FnFo3ZBX0AEXow_.jpg)
Dr. Mushtaq @mumairmushtaq and Dr. Mustache @aksinghmd from the yellow team BMT will need to set a debate BCMA BiTE vs BCMA CAR-T in next meeting #KuASHreview #mmsm @KUcancercenter #MedTwitter
Our fellows had a great time today at @KUcancercenter's #KuASHreview!
#ASH22 #leusm #mmsm #lymsm #HemeTwiiter
Photos post #KuASHreview symposium #mmsm #myeloma #USMIRC #medtwitter #MedEd @AYACOUB7 @leshune @NausheenAhmedMD @KUcancercenter @KUMedCenter @KUHospital
The Venturous Venerable Venetoclax: Dosing Strategies and Toxicity Management from Cory Perry, Clinical Hematology Pharmacist #KuASHreview #USMIRC #medtwitter #MedEd @KUcancercenter @KUHospital @KUMedCenter
Next up, @KUcancercenter very own #oncopharm @corper17 presenting on toxicities of venetoclax #kuASHreview #kubloodcancer #twitterRX
He nailed that MOA!
LSD1 inhibitor in ET: 100% achieved a platelet count of ≤400 x 109/L. Median time to ≤400 x 109/L is 10 weeks
#KuASHreview #MPNews #USMIRC #medtwitter #MedEd @KUcancercenter
Luspatercept:No significant differences in PFS
Probability of > 36 mo OS:
Very Low-Risk MDS on Luspatercept: 77.8% vs Placebo: 16.7%, OR 17.5, P = 0.0088
#KuASHreview #MDS #USMIRC #medtwitter #MedEd @KUcancercenter
Early treatment with low doses of LEN at 5 mg/day prolonged time to TD vs placebo;Risk of TD reduced by ~70%.Erythroid response was ~78% and cytogenetic response ~94% in LEN arm
• No Difference in OS, no QOL assessment #KuASHreview #MDS #USMIRC #medtwitter #MedEd @KUcancercenter
Dr. Jesus Lugo @KUcancercenter presenting updates in MDS from #ash22 #KuASHreview #MDS #USMIRC #medtwitter #MedEd
Unfortunately, we didn’t take a picture during the debate (BiTE vs CAR-T) but this is How close it ended between me and @AtrashShebli after the debate #KuASHreview #mmsm #myeloma #USMIRC #medtwitter #MedEd @KUcancercenter
Speakers today covering many topics from #ash22 #KuASHreview #mmsm #myeloma #USMIRC #medtwitter #MedEd @KUcancercenter @AtrashShebli @NausheenAhmedMD @AYACOUB7 @KUHospital @KUMedCenter
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers